Cargando…

Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis

Ustekinumab has recently been approved for the treatment of ulcerative colitis (UC) based on data from clinical trials. However, the effectiveness of ustekinumab in patients with UC in a real-world setting remains unclear. Hence, in this meta-analysis, we aimed to evaluate the effectiveness of ustek...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uchida, Genta, Nakamura, Masanao, Yamamura, Takeshi, Tsuzuki, Tomoyuki, Kawashima, Hiroki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nagoya University 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565585/ https://www.ncbi.nlm.nih.gov/pubmed/37829481 http://dx.doi.org/10.18999/nagjms.85.3.402

Ejemplares similares

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
por: Rodríguez Meza, Miguel Ricardo, et al.
Publicado: (2022)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
por: Hong, Simon J, et al.
Publicado: (2021)

The effects of ustekinumab on small intestinal lesions and stenotic lesions
por: Wada, Hirotaka, et al.
Publicado: (2022)

Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Diffuse Panbronchiolitis in a Patient With Ulcerative Colitis Treated With Ustekinumab
por: Marmor, Meghan, et al.
Publicado: (2023)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
por: Nakamura, Masanao, et al.
Publicado: (2020)

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
por: Lucaciu, Laura A., et al.
Publicado: (2021)

Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis
por: Maeda, Keiko, et al.
Publicado: (2022)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Diagnostic performance of endoscopic classifications for neoplastic lesions in patients with ulcerative colitis: A retrospective case-control study
por: Kida, Yuichi, et al.
Publicado: (2022)

Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis
por: Hu, Kelly A., et al.
Publicado: (2022)

Ustekinumab is effective against ulcerative colitis with intestinal stenosis: A case report
por: Liu, Ailing, et al.
Publicado: (2022)

Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis
por: Godoy Brewer, Gala M, et al.
Publicado: (2021)

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy
por: Pavlidis, Polychronis, et al.
Publicado: (2022)

Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
por: Rubín de Célix, Cristina, et al.
Publicado: (2022)

SUITABILITY OF SURVEILLANCE COLONOSCOPY FOR PATIENTS WITH ULCERATIVE COLITIS TO DETECT COLORECTAL CANCER: CURRENT GUIDELINES MISS SOME EARLY-STAGE CASES
por: KAMIYA, TORU, et al.
Publicado: (2015)

Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis
por: Ganzleben, Ingo, et al.
Publicado: (2020)

Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022)

Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data
por: Constantin, Joelle, et al.
Publicado: (2019)

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
por: Singh, Harpreet, et al.
Publicado: (2023)

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
por: Chien, Tzu Hsiang, et al.
Publicado: (2021)

Nomogram-based prediction of rebleeding in small bowel bleeding patients: the ‘PRSBB’ score
por: Uchida, Genta, et al.
Publicado: (2018)

Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2021)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022)

Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: A case report
por: Kakiuchi, Toshihiko, et al.
Publicado: (2022)

Real-world local recurrence rate after cold polypectomy in colorectal polyps less than 10 mm using propensity score matching
por: Saito, Masashi, et al.
Publicado: (2021)

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
por: Elberdín, Laida, et al.
Publicado: (2022)

Treatment of recalcitrant disseminated ulcerative necrobiosis lipoidica with ustekinumab
por: McMullan, Patrick, et al.
Publicado: (2023)

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
por: Hoffmann, Peter, et al.
Publicado: (2019)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review
por: Luttropp, Karin, et al.
Publicado: (2020)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_khv00rlrpsrm12e2dkm8m75ksi